Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone

OBJECTIVE: Prostate-specific antigen (PSA) has been a cornerstone in diagnosing and monitoring prostate cancer. With the advent of advanced hormonal therapies, such as the combination of androgen deprivation therapy (ADT) and abiraterone acetate plus prednisone (AAP+ADT), understanding PSA's prognos...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	L. Lou, J. Wei, S. Ma, W. Chen, X.-L. Cao, F.-H. Sun
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Verduci Editore 2024-11-01
סדרה:	World Cancer Research Journal
נושאים:	prostate-specific antigen metastatic castration-sensitive prostate cancer androgen deprivation therapy abiraterone acetate prognostic factors
גישה מקוונת:	https://www.wcrj.net/wp-content/uploads/sites/5/2024/11/e2850.pdf
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!